Pathophysiology and clinical meaning of small resistance artery remodeling Enrico Agabiti RoseiDamiano Rizzoni Invited Commentary Pages: 79 - 80
The metabolic effects of angiotensin-receptor blockers Michael L. TuckDalila B. Corry Clinical Trials Report Pages: 85 - 87
Metabolic syndrome and endothelial dysfunction Alessia FornoniLeopoldo Raij OriginalPaper Pages: 88 - 95
Advanced-glycation end products in insulin-resistant states Georgia SoldatosMark E. CooperKarin A. M. Jandeleit-Dahm OriginalPaper Pages: 96 - 102
The metabolic syndrome in the Asian population Hiromi RakugiToshio Ogihara OriginalPaper Pages: 103 - 109
Metabolic syndrome therapy: Prevention of vascular injury by antidiabetic agents Ligia J. DominguezJames R. Sowers OriginalPaper Pages: 110 - 116
ACE inhibitors in patients with vascular disease: Should the peace trial change medical practice? Robert M. Carey Clinical Trials Report Pages: 119 - 120
Is angiotensin II made inside or outside of the cell? Wenxia ChaiA. H. Jan Danser OriginalPaper Pages: 124 - 127
Role of angiotensin III in hypertension Annabelle Reaux-Le GoazigoXavier IturriozCatherine Llorens-Cortes OriginalPaper Pages: 128 - 134
Molecular evidence of tissue renin-angiotensin systems: A focus on the brain Koji SakaiCurt D. Sigmund OriginalPaper Pages: 135 - 140
The salt paradox and its possible implications in managing hypertensive diabetic patients Volker VallonRoland BlantzScott Thomson OriginalPaper Pages: 141 - 147
Cellular mechanisms and treatment of diabetes vascular complications converge on reactive oxygen species Catharine I. Whiteside OriginalPaper Pages: 148 - 154